# A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

> **NCT02906605** · PHASE2 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** JNJ-809
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT02906605
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study start delayed due to pending collection and analysis of additional phase 1 data.
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906605, "A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02906605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*